

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

Claim 1. (Currently Amended) A method of inactivating enveloped viruses contaminating in a viral preparation predominantly containing ~~comprising nonenveloped~~ adenoviruses ~~susceptible to contamination by enveloped viruses, according to~~ in which a sufficient quantity of a solvent is introduced into the said viral preparation and the said solvent is allowed to act at a temperature between -5°C to ~~about~~ +50°C, at a pH of between 5 to 9 for a period which is sufficiently long to significantly reduce the quantity of enveloped viruses present in the said viral preparation, wherein said method of inactivation is capable of preserving at least 80% of the infectious activity of said adenoviruses.

Claim 2. (Currently Amended) ~~The Method~~ method of inactivating enveloped viruses according to Claim 1, ~~according to which~~ wherein the solvent is ~~chosen~~ selected from the group consisting of ~~the~~ dialkyl phosphates and ~~the~~ trialkyl phosphates.

Claim 3. (Currently Amended) ~~The Method~~ method of inactivating enveloped viruses according to Claim 2, ~~according to which~~ wherein each of the alkyl groups of the dialkyl or trialkyl phosphate independently comprises from 1 to 10 carbon atoms.

Claim 4. (Currently Amended) ~~The Method~~ method of inactivating enveloped viruses according to Claim 1, ~~according to which~~ wherein the quantity of solvent introduced into the ~~said~~ viral preparation is between 0.001% and 10%.

Claim 5. (Currently Amended) ~~The Method~~ method of inactivating enveloped viruses according to Claim 1, ~~according to which~~ the ~~said~~ method is carried out in the presence of a solubilizing agent.

Claim 6. (Currently Amended) ~~The Method~~ method of inactivating enveloped viruses according to Claim 5, ~~according to which~~ wherein the solubilizing agent is a Tween.

Claim 7. (Currently Amended) ~~The Method~~ method of inactivating enveloped viruses according to Claim 5, ~~according to which~~ wherein the quantity of solubilizing agent introduced into the ~~said~~ viral preparation is between 0.001% and 10%.

Claim 8. (Currently Amended) The Method of inactivating enveloped viruses according to Claim 1, ~~according to which~~ wherein the said solvent is allowed to act, ~~optionally in the presence of the said solubilizing agent,~~ at a temperature of between about +4°C and +37°C.

Claim 9. (Currently Amended) The Method method of inactivating enveloped viruses according to Claim 1, ~~according to which~~ wherein the said solvent is allowed to act, ~~optionally in the presence of the said solubilizing agent,~~ at a pH of between 6.5 and 8.5.

Claim 10. (Currently Amended) The Method method of inactivating enveloped viruses according to Claim 1, ~~according to which~~ wherein the said solvent is allowed to act, ~~optionally in the presence of the solubilizing agent,~~ for a period of between 15 ~~min~~ minutes and 24 ~~h~~ hours.

Claim 11. (Currently Amended) The Method method of inactivating enveloped viruses according to Claim 1, ~~according to which~~ wherein the said method is carried out with stirring.

Claim 12. (Currently Amended) ~~The Method~~ method of inactivating enveloped viruses according to Claim 1, ~~according to which~~ wherein the said method is carried out under conductivity conditions of between about 5 and about 500 mS/cm.

Claims 13-15. (Canceled)

Claim 16. (New) The method of inactivating enveloped viruses of claim 3, wherein said solvent is tri-n-butyl phosphate (TNBP).

Claim 17. (New) The method of inactivating enveloped viruses of claim 16, wherein the quantity of TNBP introduced into the said viral preparation is between 0.1% and 0.6% (volume/volume).

Claim 18. (New) The method of inactivating enveloped viruses of claim 17, wherein the quantity of TNBP introduced into the said viral preparation is in the region of 0.3% (volume/volume).

Claim 19. (New) The method of inactivating enveloped viruses of claim 7, wherein the quantity of solubilizing agent introduced into the said viral preparation is between 0.01% and 5% (volume/volume).

Claim 20. (New) The method of inactivating enveloped viruses of claim 19, wherein the quantity of solubilizing agent introduced into the said viral preparation is between 0.1 % and 2 % (volume/volume).

Claim 21. (New) The method of inactivating enveloped viruses of claim 20, wherein the solubilizing agent introduced into the said viral preparation is Tween 80.

Claim 22. (New) The method of inactivating enveloped viruses of claim 8, wherein the temperature is between +15°C and +25°C.

Claim 23. (New) The method of inactivating enveloped viruses of claim 9, wherein the pH is 8.5.

Claim 24. (New) The method of inactivating enveloped viruses of claim 10, wherein the period of time is of between 1 hour and 5 hours.

Claim 25. (New) The method of inactivating enveloped viruses of claim 12, wherein the conductivity conditions are between 10 and 100 mS/cm.

Claim 26. (New) The method of inactivating enveloped viruses of claim 1, wherein TNBP at a final concentration of between 0.1 % and 0.6 % (volume/volume) and

Tween 80 at a final concentration of between 0.5% and 2% (volume/volume) are introduced into said viral preparation, said TNBP and said Tween 80 are allowed to act at room temperature at a pH of 8.5 for a period of time between 1 hour and 5 hours, wherein at least 80% of the infectious activity of said adenoviruses is preserved.

Claim 27. (New) The method of inactivating enveloped viruses of claim 1, wherein said adenovirus is recombinant.

Claim 28. (New) The method of inactivating enveloped viruses of claim 1, wherein said adenovirus is replication-defective.

Claim 29. (New) The method of inactivating enveloped viruses according to Claim 8, wherein the solvent is allowed to act in the presence of the solubilizing agent.

Claim 30. (New) The method of inactivating enveloped viruses according to Claim 9, wherein the solvent is allowed to act in the presence of the solubilizing agent.

Claim 31. (New) The method of inactivating enveloped viruses according to Claim 10, wherein the solvent is allowed to act in the presence of the solubilizing agent.